In the last trading session, 2.65 million Novavax, Inc (NASDAQ:NVAX) shares changed hands as the company’s beta touched 2.12. With the company’s per share price at $8.51 changed hands at -$0.09 or -1.16% during last session, the market valuation stood at $1.36B. NVAX’s last price was a discount, traded about -180.38% off its 52-week high of $23.86. The share price had its 52-week low at $3.53, which suggests the last value was 58.52% up since then. When we look at Novavax, Inc’s average trading volume, we note the 10-day average is 5.71 million shares, with the 3-month average coming to 5.30 million.
Analysts gave the Novavax, Inc (NVAX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended NVAX as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Novavax, Inc’s EPS for the current quarter is expected to be -0.65.
Novavax, Inc (NASDAQ:NVAX) trade information
Instantly NVAX was in red as seen at the end of in last trading. With action -12.86%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 5.78%, with the 5-day performance at -12.86% in the red. However, in the 30-day time frame, Novavax, Inc (NASDAQ:NVAX) is -3.57% down. Looking at the short shares, we see there were 36.92 million shares sold at short interest cover period of 10.86 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 61.32% from its current market value. According to analyst projections, NVAX’s forecast low is 14 with 25 as the target high. To hit the forecast high, the stock’s price needs a -193.77% plunge from its current level, while the stock would need to soar -64.51% for it to hit the projected low.
Novavax, Inc (NVAX) estimates and forecasts
Data shows that the Novavax, Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -43.75% over the past 6 months, a 75.79% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach -26.39% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 90.92M. 1 analysts are of the opinion that Novavax, Inc’s revenue for the current quarter will be 47.5M. The company’s revenue for the corresponding quarters a year ago was 291.34M and 93.86M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -68.79%. The estimates for the next quarter sales put growth at -49.39%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.55%. The 2025 estimates are for Novavax, Inc earnings to increase by 76.43%.
NVAX Dividends
Novavax, Inc is expected to release its next quarterly earnings report in February.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.41% of Novavax, Inc shares while 60.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 62.77%. There are 60.00% institutions holding the Novavax, Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 10.0599% of the shares, roughly 14.08 million NVAX shares worth $178.19 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.4669% or 11.85 million shares worth $149.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF . With 4.86 shares estimated at $41.33 million under it, the former controlled 3.03% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.52% of the shares, roughly 4.04 shares worth around $34.33 million.
